Skip to content

Trunerox™

Adjunctive Treatment of Seizures Associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS)

Trunerox™ 10% CBD Oral Solution

Adjunctive treatment of seizures associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS)

Trunerox™ is a pharmaceutical drug with proprietary formulation manufactured under GMP standards and utilizing the Company’s API. Clinical indications show Trunerox™ shows potential as an adjunctive treatment for seizures associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS). 

Marketing authorization has been obtained in Colombia by INVIMA in Q1, 2024. Commercialization in Colombia is expected for late 2024 with opportunities to expand into other South and Central American markets.

Trunerox™ is expected to launch in the second half of 2024.

Pharmaceutical Pipeline and Drug Candidates

Designed to Address 5 Major Clinical Areas
Leveraging the company’s scientific platform and vertical integration to deliver proprietary and accessible finished products, these cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Candidates are in various stages of R&D, pre-clinical to real world evidence studies and or registration stage.

Contact Us